ATC Abstracts

American Transplant Congress abstracts

2017 American Transplant Congress » Poster Session A: Clinical Science: Liver - Hepatocellular Carcinoma and Cholangiocarcinoma Malignancies

Date: Saturday, April 29, 2017

Time: 5:30pm-7:30pm

Location: Hall D1

Session Type: Poster Session

Meeting: 2017 American Transplant Congress

5:30pm-7:30pm
A New Strategy for Loco-Regional Therapy of Hepatocellular Carcinoma: Stereotactic Body Radiotherapy as a Bridge to Liver Transplantation.

T. Uemura,1 A. Kirichenko,2 M. Bunker,3 M. Vincent,1 L. Machado,1 A. Singhal,1 N. Thai.1

5:30pm-7:30pm
Comparison of Local Recurrence Rates Between Endhole vs Anti-Reflux Catheters in Patients Undergoing DEB-TACE for Solitary LR-5 HCC Tumors.

A. Arepally, L. Stein, R. Shrestha, M. Tully, S. Citron, A. Cherian, H. Pollinger, M. Bosley, R. Raymond.

5:30pm-7:30pm
Comparison of Locoregional Therapies for Hepatocellular Carcinoma in Liver Transplant Recipients.

M. Chen, B. Philosophe.

5:30pm-7:30pm
Comparison of Long-Term Survival Outcome Between Primary Liver Transplantation and Hepatic Resection with Consequent Salvage Transplantation for Hepatocellular Carcinoma within Milan Criteria – A Single-Center Experience.

K. Ng,1 K. Chok,1 A. Chan,1 T. Wong,1 J. Fung,2 C.-M. Lo.1

5:30pm-7:30pm
Different Prognostic Factors for Early and Late Recurrence After Adult Living Donor Liver Transplantation for Hepatocellular Carcinoma.

S. Hong, K.-W. Lee, H.-S. Kim, S.-W. Ahn, K. Yoon, H. Kim, N.-J. Yi, K.-S. Suh.

5:30pm-7:30pm
Effect of Embolization History and Tumor Treatment Response on Plasma TGFβ in HCC Patients Listed for Liver Transplantation.

P. Thevenot,1 K. Núñez,1 J. Gonzalez-Rosario,1 T. Sandow,1 A. Alharbi,1 A. Bokhari,1 D. Wyczechowska,2 A. Ochoa,2 A. Cohen.1

5:30pm-7:30pm
Expanded Criteria for HCC in Liver Transplantation.

M. Haberal,1 A. Akdur,1 G. Moray,1 G. Arslan,2 F. Ozcay,3 H. Selcuk,4 H. Ozdemir.5

5:30pm-7:30pm
Favorable Long-Term Prognosis of Hepatitis B Surface Antigen Positive Intrahepatic Cholangiocarcinoma for Both Hepatic Resection and Incidental Liver Transplantation via Inhibiting Cancer-Associated Lymphangiogenesis.

J. Gu, S. Jeong, M. Sha, J. Zhang, Q. Xia.

5:30pm-7:30pm
HCC and Cardiac Cirrhosis After the Fontan Procedure in a Patient with Congenital Heart Disease and Situs Inversus.

P. Nguyen, N. Galvan, M. Kueht, C. O'Mahony, R. Cotton, A. Rana, J. Goss.

5:30pm-7:30pm
Hepatic Artery and Biliary Complications in Liver Transplant Recipients with Radioembolization Bridging Treatment for Hepatocellular Carcinoma.

S. Radunz,1 J. Treckmann,1 F. Saner,1 S. Müller,2 J. Theysohn,3 A. Paul,1 T. Benkö.1

5:30pm-7:30pm
Incidental Hepatocellular Carcinoma in Explanted Livers: An Assessment After LIRADS Introduction.

S. Garcia Aroz,1 D. Ludwig,2 K. Fowler,2 N. Vachharajani,1 M. Xu,1 Y. Lin,1 M. Doyle,1 W. Chapman.1

5:30pm-7:30pm
Is There Any Difference Between ABO-Incompatible and ABO-Compatible Liver Transplantation? Oncologic Aspect.

J. Lee,1 J. Lee,1 S. Song,1 S.-K. Kwon,1 D. Kim,1 J. Lee,2 M. Kim,1 G. Choi,1 J. Choi,1 D. Han,1 S. Kim,1 D. Joo.1

5:30pm-7:30pm
Outcome After Living Donor Liver Transplantation for Hepatocellular Carcinoma in Elderly Patients > 65 Years: Assessing the Long Term Survival.

A. Thorat, S.-C. Hsu, L.-B. Jeng, H.-R. Yang, P.-C. Li, C.-C. Yeh, T.-H. Chen, K.-S. Poon.

5:30pm-7:30pm
Outcomes Following Transplantation for Hepatocellular Carcinoma.

P. Tabrizian, K. Nakazawa, J. Prigoff, M. Schwartz, S. Florman.

5:30pm-7:30pm
Pre-TACE Immune Status Correlates with Treatment Response and Tumor Biology in HCC as a Bridge to Transplant.

T. Sandow,1 H. Bohorquez,2 D. Kirsch,1 A. Albar,1 P. Thevenot,3 K. Nunez,3 D. DeVun,1 J. Gimenez,1 G. Galliano,4 A. Cohen,2 G. Loss,2 D. Kay,1 P. Gulotta.1

5:30pm-7:30pm
Predicting Recurrence Prior to Transplant: The Response of HCC to Chemoembolization.

T. Sandow,1 H. Bohorquez,2 D. Kirsch,1 P. Thevenot,3 K. Nunez,3 A. Albar,1 D. DeVun,1 J. Gimenez,1 G. Galliano,4 A. Cohen,2 G. Loss,2 D. Kay,1 P. Gulotta.1

5:30pm-7:30pm
Prognostic Significance of Preoperative Neutrophil-Lymphocyte Ratio in Patients Undergoing Liver Transplantation with Hepatocellular Carcinoma within Milan Criteria.

S.-K. Kwon,1 J. Lee,1 S. Song,1 J. Lee,1 D. Kim,1 J. Lee,2 M. Kim,1 G. Choi,1 J. Choi,1 D. Han,1 S. Kim,1 D. Joo.1

5:30pm-7:30pm
Re-Evaluation of Imaging Studies in Patients with Hepatocellular Carcinoma at a Transplant Center Impacts Patient Care.

A. Kardashian, B. Madani, C. Frenette.

5:30pm-7:30pm
Recurrent HCC After Radiofrequency Ablation or Liver Resection Can Be Effectively Treated with Salvage Transplantation.

H. Muaddi,1 D. Al-Adra,1 J. Shaw,1 D. Grant,1 P. Greig,1 I. McGilvray,1 M. Cattral,1 A. Wei,1 C.-A. Moulton,1 J. Kachura,2 R. Beecroft,2 M. Selzner,1 A. Ghanekar,1 S. Gallinger,1 S. Cleary,1 G. Sapisochin.1

5:30pm-7:30pm
Serum AFP Greater Than 200 ng/ml as a Predictor for Low Survival in Patients with Hepatocelullar Carcinoma Recurrence in a Brazilian Multicentric Study.

I. Boin,1 M. Possatto,1 E. Ataide,1 R. Silva,2 R. Silva,2 H. Felicio,2 L. Amado,3 A. Lima,3 T. Seva-Pereira.1

5:30pm-7:30pm
The Glasgow Prognostic Score and Its Variants Predict Mortality in Living Donor but Not in Deceased Donor Liver Transplantation for Hepatocellular Carcinoma: A Double-Center Validation Study.

A. Kaltenborn,1 J. Gwiasda,1 N. Heits,2 F. Braun,2 H. Schrem.1

5:30pm-7:30pm
The Impact of the Donor Risk Index on Tumor Free Survival in Patients Undergoing Liver Transplantation with Hepatocellular Carcinoma.

D. Moonka,1 S. Nagai,2 A. Harper, R. Salgia.1

5:30pm-7:30pm
Which Way to Go, Liver Resection or Liver Transplantation for Hepatocellular Carcinoma in Child A Liver Cirrhosis.

K. Yoon, K.-W. Lee, H. Kim, D. Oh, H.-S. Kim, S. Ahn, S. Hong, N.-J. Yi, K.-S. Suh.

5:30pm-7:30pm
Women in the United States Receive More Resections and Ablations for Hepatocellular Carcinoma Than Men.

L. Sobotka,1 A. Hinton,2 L. Conteh.1

« View all sessions from the 2017 American Transplant Congress